Total Payments
$1.2M
2024 Payments
$119.31
Companies
14
Transactions
140
Medicare Patients
9,796
Medicare Billing
$914,123
Payment Breakdown by Category
Research$1.2M (99.9%)
Food & Beverage$787.38 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 122 | 99.9% |
| Food and Beverage | $787.38 | 18 | 0.1% |
Payments by Type
Research
$1.2M
122 transactions
General
$787.38
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $897,165 | 106 | $0 (2021) |
| Bausch Health US, LLC | $257,450 | 7 | $0 (2021) |
| Kala Pharmaceuticals, Inc. | $73,393 | 15 | $0 (2020) |
| AbbVie Inc. | $5,272 | 2 | $0 (2023) |
| Sun Pharmaceutical Industries Inc. | $123.20 | 1 | $0 (2022) |
| Alcon Laboratories Inc | $119.67 | 1 | $0 (2017) |
| Kowa Research Institute, Inc. | $100.00 | 1 | $0 (2023) |
| Oyster Point Pharma, Inc. | $94.99 | 1 | $0 (2024) |
| Alcon Vision LLC | $72.73 | 1 | $0 (2019) |
| Tarsus Pharmaceuticals, Inc. | $24.32 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $119.31 | 2 | Oyster Point Pharma, Inc. ($94.99) |
| 2023 | $5,372 | 3 | AbbVie Inc. ($5,272) |
| 2022 | $163.88 | 3 | Sun Pharmaceutical Industries Inc. ($123.20) |
| 2021 | $254,971 | 7 | Bausch Health US, LLC ($254,950) |
| 2020 | $75,264 | 11 | Allergan, Inc. ($72,740) |
| 2019 | $676,263 | 57 | Allergan Inc. ($602,822) |
| 2018 | $133,044 | 34 | Allergan Inc. ($132,998) |
| 2017 | $88,705 | 23 | Allergan Inc. ($88,585) |
All Payment Transactions
140 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Tarsus Pharmaceuticals, Inc. | XDEMVY (Drug) | Food and Beverage | In-kind items and services | $24.32 | General |
| Category: DEMODEX BLEPHARITIS | ||||||
| 03/12/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug) | Food and Beverage | In-kind items and services | $94.99 | General |
| Category: Dry eyes | ||||||
| 06/02/2023 | Kowa Research Institute, Inc. | — | Food and Beverage | Cash or cash equivalent | $100.00 | General |
| 03/09/2023 | AbbVie Inc. | DURYSTA (Drug) | — | Cash or cash equivalent | $1,935.00 | Research |
| Study: Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension • Category: EYE CARE | ||||||
| 01/11/2023 | AbbVie Inc. | DURYSTA (Drug) | — | Cash or cash equivalent | $3,337.00 | Research |
| Study: Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension • Category: EYE CARE | ||||||
| 10/12/2022 | Sun Pharmaceutical Industries Inc. | Cequa (Drug) | Food and Beverage | In-kind items and services | $123.20 | General |
| Category: Ophthalmology | ||||||
| 08/26/2022 | Bausch & Lomb Americas Inc. | VYZULTA (Drug) | Food and Beverage | In-kind items and services | $19.55 | General |
| Category: Ophthalmology | ||||||
| 03/03/2022 | EYEVANCE PHARMACEUTICALS LLC | TobraDex ST (Drug) | Food and Beverage | In-kind items and services | $21.13 | General |
| Category: OPHTHALMIC | ||||||
| 12/15/2021 | Bausch Health US, LLC | — | — | Cash or cash equivalent | $56,050.00 | Research |
| Study: A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction (Mojave Study) | ||||||
| 09/02/2021 | Allergan, Inc. | RESTASIS MULTIDOSE (Drug) | Food and Beverage | In-kind items and services | $20.82 | General |
| Category: DRY EYE | ||||||
| 08/20/2021 | Bausch Health US, LLC | — | — | Cash or cash equivalent | $23,400.00 | Research |
| Study: A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction (Mojave Study) | ||||||
| 08/04/2021 | Bausch Health US, LLC | — | — | Cash or cash equivalent | $40,950.00 | Research |
| Study: A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction (Mojave Study) | ||||||
| 06/15/2021 | Bausch Health US, LLC | — | — | Cash or cash equivalent | $70,200.00 | Research |
| Study: A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction (Mojave Study) | ||||||
| 05/21/2021 | Bausch Health US, LLC | — | — | Cash or cash equivalent | $52,650.00 | Research |
| Study: A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction (Mojave Study) | ||||||
| 04/06/2021 | Bausch Health US, LLC | — | — | Cash or cash equivalent | $11,700.00 | Research |
| Study: A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction (Mojave Study) | ||||||
| 12/03/2020 | Bausch Health US, LLC | — | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction (Mojave Study) | ||||||
| 10/20/2020 | Allergan, Inc. | — | — | Cash or cash equivalent | $50.00 | Research |
| Study: AN EXTENSION TRIAL TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BIMATOPROST SR IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION | ||||||
| 10/05/2020 | Allergan, Inc. | DURYSTA (Drug) | Food and Beverage | In-kind items and services | $22.12 | General |
| Category: GLAUCOMA | ||||||
| 02/21/2020 | Allergan, Inc. | LUMIGAN (Drug) | — | Cash or cash equivalent | $6,708.90 | Research |
| Study: An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension • Category: OPHTHALMOLOGY | ||||||
| 02/20/2020 | Kala Pharmaceuticals, Inc. | INVELTYS (Drug) | Food and Beverage | In-kind items and services | $23.95 | General |
| Category: OCULAR | ||||||
| 02/13/2020 | Allergan, Inc. | — | — | Cash or cash equivalent | $36,701.35 | Research |
| Study: A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had previous laser trabeculoplasty treatment | ||||||
| 02/06/2020 | Allergan, Inc. | — | — | Cash or cash equivalent | $550.00 | Research |
| Study: A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had previous laser trabeculoplasty treatment | ||||||
| 01/22/2020 | Allergan, Inc. | — | — | Cash or cash equivalent | $1,390.80 | Research |
| Study: The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension | ||||||
| 01/22/2020 | Allergan, Inc. | — | — | Cash or cash equivalent | $200.00 | Research |
| Study: The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension | ||||||
| 01/17/2020 | Allergan, Inc. | — | — | Cash or cash equivalent | $26,566.75 | Research |
| Study: A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had previous laser trabeculoplasty treatment | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Multicenter Double Masked Randomized Vehicle-Controlled Parallel-Group study of AGN-190584 for Participants with Presbyopia | Allergan Inc. | $320,234 | 10 |
| A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction (Mojave Study) | Bausch Health US, LLC | $257,450 | 7 |
| Safety and Efficacy of Bimatoprost Sustained-Release SR in Patients With Open-Angle Glaucoma or Ocular Hypertension | Allergan Inc. | $219,232 | 48 |
| A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had previous laser trabeculoplasty treatment | Allergan Inc. | $204,841 | 11 |
| Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease | Kala Pharmaceuticals, Inc. | $73,270 | 9 |
| A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had previous laser trabeculoplasty treatment | Allergan, Inc. | $64,368 | 4 |
| The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension | Allergan Inc. | $52,958 | 17 |
| An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension | Allergan Inc. | $24,788 | 4 |
| An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension | Allergan, Inc. | $6,709 | 1 |
| Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension | AbbVie Inc. | $5,272 | 2 |
| EFFICACY AND SAFETY OF BIMATOPROST SUSTAINED-RELEASE SR IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION | Allergan Inc. | $2,350 | 6 |
| The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension | Allergan, Inc. | $1,591 | 2 |
| AN EXTENSION TRIAL TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BIMATOPROST SR IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION | Allergan, Inc. | $50.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 2,051 | 2,672 | $367,260 | $189,332 |
| 2022 | 26 | 2,296 | 2,969 | $461,510 | $212,021 |
| 2021 | 21 | 2,702 | 3,499 | $581,575 | $264,640 |
| 2020 | 24 | 2,747 | 3,625 | $517,725 | $248,130 |
Total Patients
9,796
Total Services
12,765
Medicare Billing
$914,123
Procedure Codes
88
All Medicare Procedures & Services
88 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 92014 | Established patient complete exam of visual system | Office | 2023 | 573 | 723 | $137,370 | $66,270 | 48.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 229 | 386 | $55,970 | $37,567 | 67.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 271 | 482 | $60,250 | $33,753 | 56.0% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 117 | 117 | $20,475 | $12,638 | 61.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 94 | 94 | $18,800 | $10,734 | 57.1% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 125 | 129 | $14,835 | $5,928 | 40.0% |
| 67840 | Removal of growth of eyelid | Office | 2023 | 23 | 24 | $9,600 | $5,207 | 54.2% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 192 | 237 | $8,295 | $2,811 | 33.9% |
| 68761 | Closure of tear duct opening using plug | Office | 2023 | 13 | 26 | $6,630 | $2,638 | 39.8% |
| 92250 | Photography of the retina | Office | 2023 | 89 | 90 | $8,100 | $2,593 | 32.0% |
| 92133 | Imaging of optic nerve | Office | 2023 | 81 | 81 | $4,050 | $2,136 | 52.7% |
| 92020 | Exam of the internal drainage system of eye | Office | 2023 | 94 | 98 | $4,900 | $2,045 | 41.7% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 42 | 44 | $6,600 | $1,569 | 23.8% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 55 | 74 | $3,700 | $1,384 | 37.4% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 20 | 20 | $2,400 | $1,025 | 42.7% |
| 92134 | Imaging of retina | Office | 2023 | 21 | 21 | $1,785 | $629.74 | 35.3% |
| 67820 | Removal of eyelashes using forceps | Office | 2023 | 12 | 26 | $3,500 | $404.81 | 11.6% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 655 | 832 | $151,795 | $76,184 | 50.2% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 312 | 692 | $83,040 | $44,766 | 53.9% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 150 | 150 | $26,250 | $15,454 | 58.9% |
| 93890 | Ultrasound of within the brain blood flow following medication | Office | 2022 | 71 | 71 | $28,400 | $12,791 | 45.0% |
| 93886 | Complete ultrasound of within the brain blood flow | Office | 2022 | 71 | 71 | $28,400 | $11,497 | 40.5% |
| 92083 | Exam of visual field with extended testing | Office | 2022 | 145 | 152 | $17,480 | $7,142 | 40.9% |
| 66821 | Removal of recurring cataract in lens capsule using a laser | Office | 2022 | 20 | 26 | $23,400 | $6,738 | 28.8% |
| 93892 | Ultrasound of within the brain blood flow for blood clots | Office | 2022 | 71 | 71 | $28,400 | $6,318 | 22.2% |
About Dr. Bruce Segal, MD
Dr. Bruce Segal, MD is a Ophthalmology healthcare provider based in Delray Beach, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1063467629.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bruce Segal, MD has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $119.31 received in 2024. These payments were reported across 140 transactions from 14 companies. The most common payment nature is "" ($1.2M).
As a Medicare-enrolled provider, Segal has provided services to 9,796 Medicare beneficiaries, totaling 12,765 services with total Medicare billing of $914,123. Data is available for 4 years (2020–2023), covering 88 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Delray Beach, FL
- Active Since 05/23/2006
- Last Updated 02/13/2008
- Taxonomy Code 207W00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1063467629
Products in Payments
- LUMIGAN (Drug) $225,941
- DURYSTA (Drug) $5,294
- Cequa (Drug) $123.20
- INVELTYS (Drug) $122.50
- ReSTOR (Device) $119.67
- TYRVAYA (Drug) $94.99
- ACTIVEFOCUS (Device) $72.73
- XDEMVY (Drug) $24.32
- ISTENT TRABECULAR MICRO-BYPASS STENT SYSTEM (Device) $23.83
- CRYSTALENS (Device) $22.52
- TobraDex ST (Drug) $21.13
- RESTASIS MULTIDOSE (Drug) $20.82
- VYZULTA (Drug) $19.55
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Delray Beach
Eric Rothchild, Md, MD
Ophthalmology — Payments: $16,376
Ophthalmology $16,376
Dr. Steven Rosenfeld, Md, MD
Ophthalmology — Payments: $4,587
Ophthalmology $4,587
Dr. Peter Pearlman, M.d, M.D
Ophthalmology — Payments: $3,998
Ophthalmology $3,998
Talya Kupin, Md, MD
Ophthalmology — Payments: $3,520
Ophthalmology $3,520
Robert Raden, Md, MD
Ophthalmology — Payments: $1,937
Ophthalmology $1,937
Dr. Marc Winnick, M.d, M.D
Ophthalmology — Payments: $1,705
Ophthalmology $1,705